October 31, 2019 08:30 AM EDTUpdated October 31, 11:17 PM
R&D

Sanofi's on­col­o­gy R&D group marks a pair of set­backs on isat­ux­imab/Lib­tayo com­bo as can­cer stud­ies fiz­zle out

John Carroll

Editor & Founder

Sanofi’s can­cer R&D group has suf­fered a set­back with the fail­ure of a pair of clin­i­cal tri­als match­ing their CD38 con­tender isat­ux­imab with Re­gen­eron’s PD …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times